← All organizations
Max Planck Institute
Academic/HospitalWebsite ↗
Also known as: Max-Planck Institut | Max Planck Institute for Human Cognitive and Brain Sciences | Max Planck Institute for Infection Biology | Max Planck Institute for Infection Biology (MPIIB), Berlin, Germany | Max-Planck Institute for Metabolism Research | Max-Planck-Institute, Munich | Max-Planck-Institute of Experimental Medicine | Max-Planck-Institute of Psychiatry | Max Planck Institute of Psychiatry, Munich | Max-Planck-Institute of Psychiatry Munich
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2001Last known activity
Mar 8, 2022
Timeline
1910s
- Jun 1, 1911
Max Planck Institute— Founded
Drugs by trial phase (39 distinct, 25 trials)
Phase 4 (15 own, 0 via acquisition)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (3 own, 0 via acquisition)
Phase 1 (5 own, 0 via acquisition)
Indications
Studied for
- Adrenal Insufficiency
- Amyotrophic Lateral Sclerosis
- Bipolar Disorder
- Communicable Diseases
- Depression
- Depressive Disorder
- Depressive Disorder, Treatment-Resistant
- Disease
- Infarction
- Infarction, Middle Cerebral Artery
- Infections
- Influenza, Human
- Mood Disorders
- Motor Neuron Disease
- Schizophrenia
- Sclerosis
- Stroke
- Whooping Cough
Recent trials (40)
- NCT05353504Lead sponsorN/AMar 8, 2022
- NCT04439045CollaboratorPhase 3Jun 14, 2020
- NCT03829189Lead sponsorN/AJan 14, 2019
- NCT06729658OfficialEarly Phase 1Oct 1, 2017
- NCT06729658Lead sponsorEarly Phase 1Oct 1, 2017
- NCT03162185Study chairPhase 4Apr 1, 2017
- NCT03162185Lead sponsorPhase 4Apr 1, 2017
- NCT03162185Study directorPhase 4Apr 1, 2017
- NCT03160118CollaboratorPhase 4Mar 27, 2017
- NCT02621554Overall official - principal investigatorN/AApr 1, 2016
- NCT02621554Study directorN/AApr 1, 2016
- NCT02621554Study chairN/AApr 1, 2016
- NCT02621554Lead sponsorN/AApr 1, 2016
- NCT05063058CollaboratorN/AJan 31, 2016
- NCT00916201CollaboratorPhase 1Dec 1, 2015
Details
- Founded
- Munich, DE Jun 1, 1911
- Last known activity
- Mar 8, 2022